EASD NAFLD Study Group 5th Annual Meeting
Astra Zeneca, Möndal, Sweden
8th-9th May 2017

NAFLD study group Committee

Chair: Amalia Gastaldelli
Board members: Gianluca Svegliati-Baroni, Kenneth Cusi, Hannele Yki-Järvinen, Leanne Hodson, Stefano Romeo, Michael Trauner, Giulio Marchesini
Organizing Committee: Stefano Romeo, Rosellina Margherita Mancina, Piero Pingitore

Program

MONDAY 8th May 2017

10.30-11.00	**REGISTRATION**	**Speakers upload the talks for the day**
11.00-11.10	**OPENING WORDS:** Stefano Romeo	
11.10-12.15	**SESSION 1 – GUT-LIVER AXIS**	
11.10-12.00	Fredrik Bäcked Sweden	The role of gut microbiota in the susceptibility to metabolic diseases
12.00-12.15	Gianluca Svegliati-Baroni Italy	The combination of mucus-degrading gram-negative bacteria and reduced antimicrobial peptides drives adipose tissue inflammation and NAFLD progression in mice lacking NLRP3-inflammasome.
12.15-13.00	**LUNCH**	
13.10-15.00	**SESSION 2 – LIVER DISEASE AND DIABETES MELLITUS 2** Moderator: Hannele Yki-Järvinen	
13.10-14.00	Norbert Stefan Germany	Interplay between type 2 diabetes and NAFLD
14:00-14:15	Paul Afolabi United Kingdom	The relationship between hepatic mitochondrial function and type 2 diabetes in patients with NAFLD
14:15-14:30	Chris Byrne United Kingdom	Non-alcoholic fatty liver disease-related mortality in type 2 diabetes
14:30-14:45	Karl Björkström Sweden	Histological scores for fat and fibrosis predicts development of

		type 2 diabetes in NAFLD
14:45-14:50	Roy Taylor United Kingdom	Degree of non-alcoholic fatty liver disease is the greatest metabolic abnormality in early type 2 diabetes
14:50-14:55	Diego Olschowsky Borges Portugal	Genetic or dietary derived insulin clearance impairment: the major drivers of glucose intolerance
14:55-15:00	Fátima Martins Portugal	Nitric oxide governs insulin bioavailability through controlling insulin clearance in a model of sucrose-induced hepatic lipogenesis
15:00-15:45	**SESSION 3 – MISCELLANEA** Moderator: Jussi Pihlajamäki	
15:00-15:15	Fabio Marra Italy	Cross-talk between the IDO-kynurenine pathway al IL-1 beta in experimental NASH
15:15-15:30	Kelly Bowden Davies United Kingdom	The metabolic consequences of short-term increased sedentary behaviour
15:30-15:45	Henry Wilman United Kingdom	Characterisation of liver fat in the UK Biobank cohort
15:45-15:50	Nádia Duarte Portugal	Severe Shifts in Kupffer Cell Populations Are Mirrored by Dipeptidyl Peptidase-4 (DPP-4/CD26) Activity in the Serum
15:35-15:40	Andriana Kaliora Greece	The MAST4HEALTH Consortium
15.40-16.00	**COFFEE BREAK**	
16.00-18.00	**SESSION 4 – DIAGNOSIS AND TREATMENT OF NAFLD** Moderator: Stefano Romeo	
16.00-17.00	**one on one session** Luca Valenti Italy	Liver biopsy why and when?
	Banerjee Rajarshi United Kingdom	Non-invasive diagnosis instead of liver biopsy?
17:00-17:15	Michael Feigh Denmark	Liraglutide, elafibranor and obeticholic acid show different efficacy profiles in diet-induced and genetically obese mouse models with biopsy-confirmed NASH

17:15-17:30	Henry Wilman United Kingdom	Non-invasive multiparametric MRI (LiverMultiScan^{TM}) effectively excludes NASH and liver fibrosis in at risk patients
17:30-17:45	Amalia Gastaldelli Italy	Effect of Dietary Intervention or Pioglitazone Therapy on Hepatic and Visceral Fat, Insulin Resistance and Liver Histology in Patients with NASH
17:45-17:50	Kelly Bowden Davies United Kingdom	Habitual physical activity, independent of moderate-vigorous activity, predicts amount of liver fat and metabolic health status
17:50-17:55	Deven V Parmar India	Saroglitazar magnesium in non-alcoholic steatohepatitis? A case for further clinical investigation
17:55-18:00	Manuel Romero-Gómez Spain	Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease
18:00-18:05	Mostafa Elkady Egypt	`A case report`: A Dramatic Response to Albendazole in a Case of a Large Hepatic focal lesion Mimicking Hepatocellular carcinoma``
18.05- 18.30	**AN AMAZING JOURNEY AT ASTRA-ZENECA**	
18.30-19.45	**DINNER**	
20.00	**BUS TRANSFER TO GOTHIA TOWERS**	

TUESDAY 9th May 2017

07.50	**BUS TRANSFER FROM GOTHIA TOWERS**	
08.30	**Speakers upload the talks for the day**	
09.00-10.40	**SESSION 5 – GENETICS AND MOLECULAR MECHANISMS OF NAFLD**	
	Moderator: Amalia Gastaldelli	
09.05-10.00	Stefano Romeo Sweden	Can we use genetics of NAFLD in clinical trials or practice?
10:00-10:15	Piero Pingitore Sweden	Recombinant MBOAT7 protein shows acyltransferase activity primarily transferring arachidonic acid (aa) from arachidonoyl-coa to lysophosphatidylinositol
10:15-10:30	Martijn Brouwers Netherlands	PNPLA3, TM6SF2 and MBOAT7 genotypes and coronary artery disease
10:30-10:45	Ville Männistö Finland	Liver phosphatidylcholine content decrease in NASH is not explained by PEMT rs7946 genotype
10:45-11:00	Paula Walle Finland	Altered methylation of FADS2 in NASH is partly explained by FADS2 genotypes
11:00-11:10	**COFFEE BREAK**	
11.10-13.00	**SESSION 6 – DIET, DISLYPIDEMIA, LIPOTOXICITY IN NAFLD**	
	Moderator: Gianluca Svegliati-Baroni	
11.10-12.00	**Chrystopher Byrne** United Kingdom	Dietary risk factors and interventions in NAFLD
12:00-12:15	Kitt Petersen	Direct Assessment of Hepatic Mitochondrial Oxidation and Pyruvate Cycling in Non Alcoholic Fatty Liver Disease by ^{13}C Magnetic Resonance Spectroscopy
12:15-12:30	Panu Luukkonen Finland	Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD
12:30-12:45	Fredrik Rosqvist Sweden	Plasma ceramides are modified by dietary fat quality and are related to liver fat accumulation and lipogenic markers during overfeeding
12:45-12:50	John Jones	Differential fractional synthetic

and elongation rates of hepatic saturated fatty acids and oleate from [U-^{13}C]glucose presented alongside unlabeled fructose in healthy mice

13.00-14.00 **working LUNCH for collaborative initiatives**

The meeting is kindly sponsored by Astra-Zeneca and University of Gothenburg